Section 5: Patient Safety and Quality Assurance

5PSQ-083

MARIBAVIR-INDUCED TOXIC EPIDERMAL NECROLYSIS IN A LIVER TRANSPLANT PATIENT: A CASE REPORT.

5PSQ-082

THIRD-GENERATION HOSPITAL-EXCLUSIVE CEPHALOSPORINS: DIFFERENT SAFETY PROFILES?

5PSQ-081

SATISFACTION OF PHYSICIANS AND HOSPITAL PHARMACISTS OF A HYPERSENSITIVITY DOCUMENTATION TOOL WITH DE-LABELING FEATURE IN CLINICAL PRACTICE

5PSQ-080

CLINICAL INTERVENTIONS IN PATIENTS UNDERGOING ANTIPARKINSONIAN TREATMENT: THE IMPORTANCE OF CORRECT RECONCILIATION

5PSQ-079

PHARMACEUTICAL INTERVENTIONS IN A HEALTH MANAGEMENT AREA

5PSQ-078

HYPOPHOSPHATEMIA AFTER FERRIC CARBOXYMALTOSE ADMINISTRATION IN A COHORT OF ELDERLY PATIENTS WITH HIP FRACTURE

5PSQ-077

ADEQUATE NUTRITIONAL THERAPY IN CRITICAL PATIENTS WITH CORONAVIRUS DISEASE (COVID-19)

5PSQ-076

EFFICACY AND SAFETY OF NIVOLUMAB MONOTHERAPY VS NIVOLUMAB PLUS IPILIMUMAB IN RENAL CELL CARCINOMA IN CLINICAL PRACTICE

5PSQ-075

ADHERENCE TO LOCAL ANTIBIOTIC PRESCRIBING GUIDELINES WITHIN 48 HOURS OF INPATIENT ADMISSION

5PSQ-074

PHARMACEUTICAL INTERVENTIONS IN PAIN MANAGEMENT

5PSQ-073

RISK SCORE FOR DRUG DISCREPANCY AND ADHERENCE IN CLINICAL TRIAL PATIENTS

5PSQ-072

TREATMENT WITH GALCANEZUMAB IN REAL WORLD DATA: SAFETY.

5PSQ-071

MULTIDISCIPLINARY MANAGEMENT OF DRESS SYNDROME: A CASE REPORT

5PSQ-070

DUPILUMAB IS A MONOCLONAL ANTIBODY USED FOR THE TREATMENT OF ATOPIC DERMATITIS. THIS STUDY EVALUATES THE EFFECTIVENESS AND PERSISTENCE. DUPILUMAB PRESENTS GOOD EFFECTIVENESS AND PERSISTENCE.

5PSQ-069

COMPARISON OF RENAL GLOMERULAR FILTRATION ESTIMATION FORMULAS IN VANCOMYCIN PHARMACOKINETIC MONITORING

Pages